Internal Med

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Yeh ETH et al. - In this article the authors review the incidence of cardiotoxicity caused by commonly used chemotherapeutic agents as well as discuss the pathogenesis, diagnosis, management, and prevention of these cardiovascular side effects. Cardiotoxicity related to anticancer treatment is important to recognize as it may have a significant impact on the overall prognosis and survival of cancer patients, and it is likely to remain a significant challenge for both cardiologists and oncologists in the future due to an increasing aging population of patients with cancer and the introduction of many new cancer therapies.

Related Articles

Trastuzumab-Induced Cardiotoxicity
Oncology Nursing Forum, 11/18/09    Relevance Score: 85%

Chronic doxorubicin cardiotoxicity is mediated by oxidative DNA damage-ATM-p53-apoptosis pathway and attenuated by pitavastatin through the inhibition of Rac1 activity
Journal of Molecular and Cellular Cardiology, 10/20/09    Relevance Score: 84%

The art of healing broken hearts in breast cancer patients: Trastuzumab and heart failure
Experimental and Clinical Cardiology, 11/16/09    Relevance Score: 82%

Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines
Journal of Clinical Oncology, 10/30/09    Relevance Score: 80%

Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer
Trends in Pharmacological Sciences, 10/29/09    Relevance Score: 80%


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address